L.Acidophilus contains “friendly” bacteria (Lactobacillus acidophilus). Due to the special manufacturing technology it remains effective during the whole period of shelf life.
The product has been manufactured using high quality pure raw materials and the technology that ensures all their beneficial properties intact, in strict compliance with GMP and TÜV regulations.
Our digestive tract is host to about 400 different kinds of bacteria, some of them are harmful, some are “friendly”. The total weight of these bacteria would come to nearly one-two kilograms.
Nowadays the normal intestinal microflora is often called “the extracorporeal organ of the body”, to stress its significance for our health. The "friendly" microorganisms are called probiotics, meaning "for life."
The balance of the intestine microflora is a key to good health. Unfortunately unbalanced diet, medication (especially antibiotics), alcohol can affect the normal balance of bacteria, as well as stress, excess exposure to ultraviolet light, viral and bacterial infections, hormonal imbalance.
L.Acidophilus contains “friendly” bacteria (Lactobacillus acidophilus), which normally inhabit the small intestine.
Taking L.Acidophilus as a dietary supplement will help normalize intestine microflora and maintain it healthy.
Researches show that Lactobacillus acidophilus suppresses harmful bacteria and help fight intestinal disorders. L.Acidophilus helps to control yeast overgrowth, such as candida. The colonies of friendly bacteria present in sufficient numbers within the vaginal lining form the protective barrier against infections.
L.Acidophilus normalizes digestion, helps decrease flatulence, and control bad breath.
L.Acidophilus helps to strengthen the immune system; promotes better absorption of calcium and iron; increases protein assimilation, enhances digestion of milk sugar (lactose) and aids in the production of vitamins B.
Some researches show that Lactobacillus acidophilus can help lower the cholesterol level thus reducing the risk of coronary heart disease.
L.Acidophilus is recommended after taking antibiotics, birth control pills, after chemotherapy.
Regular intake of L.Аcidophilus will help to maintain good health and well-being.
It is recommended to take L.Аcidophilus in combination with exclusive Santegra®’s product FortiFi™ – a source of dietary fiber that effectively promote the growth of beneficial bacteris in the colon.
Per one capsule:
Lactobacillus acidophilus – 2.5 billion CFU.
Packaging size: 60 capsules.
As a dietary supplement take 1 capsule with a large glass of water daily for 30 - 40 days.
Metchnikoff, a Nobel Prize winner, was the first researcher to link probiotics with a longer lifespan. In 1908 Metchnikoff proposed that Lactobacillus acidophilus played an important role in the prolongation of human life through its role in improving the intestinal environment. His work at the Pasteur Institute in the early 1900s linked the soured milk yogurt eaten by Bulgarian peasants with their ability to live decades longer than the "expected" lifespan at the time.
L.Аcidophilus contains Lactobacillus acidophilus (2.5 billion CFU) obtained by lyophilization.
Lyophilization or freeze drying is a process in which water is removed from a product after it is frozen and placed under a vacuum, allowing the ice to change directly from solid to vapor without passing through a liquid phase. The word lyophilized is derived from the Greek "made solvent-loving".
The process consists of three separate, unique, and interdependent processes; freezing, primary drying (sublimation), and secondary drying (desorption).
Lyophilization is a way of drying something that minimizes damage to its internal structure. Because lyophilization is a relatively complex and expensive form of drying, it is limited to those materials which are sensitive to heat and have delicate structures and substantial value.
The advantages of lyophilization include:
• Enhanced stability of a dry powder;
• Removal of water without excessive heating of the product;
• Rapid and easy dissolution of reconstituted product.
Due to the special manufacturing technology L.Аcidophilus remains effective during the whole period of shelf life.
Small bowel bacterial overgrowth and related diarrhea is a condition that frequently accompanies anatomic disorders, surgically created blind loops or strictures with partial small bowel obstruction and although it is often controlled with antimicrobial therapy, alternative treatment may be needed. The aim of this study was to evaluate the efficacy of an oral probiotic preparation of 2 viable lyophilized strains of lactobacilli (1.5 g each) compared with placebo. Twenty two patients with proven overgrowth and chronic diarrhea are described. In random order and double-blind fashion, 2 groups of patients received identical capsules with both Lactobacillus casei and L. acidophillus strains CERELA (12 patients) (LC) and placebo (10 patients) (P) during three consecutive periods of 7 days each followed by a similar three periods of control after withdrawal. At the end of each period the mean daily number of stools, glucose breath H2 test, and symptoms were considered. Lactobacillus were investigated in feces in both groups at day 0 (baseline), on day 21 of treatment with LC and P and on day 21 after withdrawal. Compared with P a significant reduction in mean daily number of stools was achieved with LC (p < 0.005) at 15 days, and (p < 0.0005) at 21 days and the effect was sustained at 7 days and 15 days (p < 0.005) after withdrawal. With respect to breath H2 level a significant decrease in H2 concentration was noted at 7 days (p < 0.005) at 15 days, and 21 days (p < 0.0001) with LC and only a significant decrease (p < 0.005) was observed at 7 days after withdrawal. No significant changes were observed with respect to symptoms. The Lactobacillus CERELA strains were isolated from the feces in all patients LC (n = 12) on day 21, and by contrast no Lactobacillus were observed except in two patients out of seven patients after withdrawal. In summary, this study provides evidence that LC are effective for treatment of bacterial overgrowth--related chronic diarrhea, and suggest that probiotics must be used with continuity. (1)
Probiotic bacteria exhibit a variety of properties, which are unique to a particular strain. Lactobacillus acidophilus-SDC 2012, 2013 are new strains isolated from Korean infants' feces. The potential utility of Lactobacillus acidophilus-SDC 2012, 2013 in irritable bowel syndrome (IBS) was studied. Forty IBS patients were randomized into a placebo (n = 20) and probiotics group (n = 20). Four weeks of treatment with L. acidophilus-SDC 2012, 2013 was associated with a reduced score for abdominal pain or discomfort compared to the baseline (P = 0.011). The percent reduction in abdominal pain or discomfort exceeded the placebo scores by more than 20% (23.8 and 0.2% for probiotics and placebo, respectively, P = 0.003). There was a significant difference in the proportion of responders between the probiotics and placebo groups (P = 0.011). There was no drop out or adverse events for either group during the study period. Lactobacillus acidophilus-SDC 2012, 2013 appeared to have a beneficial effect in patients with IBS. Further studies are warranted. (2)
This review considers whether probiotics are effective agents for the treatment and/or prevention of bacterial vaginosis (BV). There seems to be an association between the absence of, or low concentrations of, vaginal lactobacilli and the development of BV. Many studies have suggested that the presence of H2O2-producing vaginal lactobacilli may protect against BV, although some studies do not support this hypothesis. In-vitro studies have suggested that certain specific strains of lactobacilli are able to inhibit the adherence of Gardnerella vaginalis to the vaginal epithelium and/or produce H2O2, lactic acid and/or bacteriocins, which inhibit the growth of bacteria causing BV. Most clinical trials showed that intra-vaginal administration of Lactobacillus acidophilus for 6-12 days, or oral administration of L. acidophilus or Lactobacillus rhamnosus GR-1 and Lactobacillus fermentum RC-14 for 2 months, resulted in the cure of BV (defined as a 0-1 positive score according to Amsel's criteria), and/or reduced the recurrences of BV, and/or caused an increase in vaginal lactobacilli and restoration of a normal vaginal microbiota, significantly more frequently than did a placebo, acetic acid or no treatment. (3)
Fatigue and impaired performance in athletes is well recognised and has been loosely linked to "overtraining". Reduced concentration of IgA in the saliva and increased shedding of Epstein Barr virus (EBV) have been associated with intense training in elite athletes. OBJECTIVE: To determine whether athletes presenting with fatigue and impaired performance had an immune defect relevant to defective containment of EBV infection, and whether a probiotic preparation (Lactobacillus acidophilus) shown to enhance mucosal immunity in animal models could reverse any detected abnormality. RESULTS: The fatigued athletes had clinical characteristics consistent with re-activation of EBV infection and significantly (p = 0.02) less secretion of interferon (IFN) gamma from blood CD4 positive T cells. After one month of daily capsules containing 2 x 10(10) colony forming units of L acidophilus, secretion of IFNgamma from T cells had increased significantly (p = 0.01) to levels found in healthy control athletes. A significant (p = 0.03) increase in salivary IFNgamma concentrations in healthy control athletes after the one month course of L acidophilus demonstrated in man the capacity for this probiotic to enhance the mucosal IFNgamma concentration.
CONCLUSION: This is the first evidence of a T cell defect in fatigued athletes, and of its reversal following probiotic therapy. (4)
Two controlled clinical studies were performed to examine effects of consumption of one daily serving of fermented milk (FM) (yogurt) on serum lipids. METHODS: In the first study, subjects were randomly allocated to FM containing Lactobacillus acidophilus L1 of human origin or to FM containing L. acidophilus ATCC 43211 of swine origin. In this single-blind study, subjects consumed one 200 ml serving of FM daily for 3 weeks. The second study was a double-blind, placebo-controlled, cross-over study. Subjects completed a 4-week first treatment, had a 2-week washout, and completed a second 4-week treatment. In the second study subjects consumed FM containing L. acidophilus L1 or placebo FM over 4 weeks. RESULTS: In the first study, FM containing L. acidophilus L1 was accompanied by a 2.4% (p<0.05) reduction of serum cholesterol concentration. In the second study, strain L1 reduced serum cholesterol concentration by 3.2% (p<0.05) in the first treatment period. In the second treatment period there were no significant changes in serum cholesterol concentration. Combined analysis of the two L1 treatment studies demonstrated a 2.8% (p<0.01) reduction in serum cholesterol concentration. CONCLUSION: Since every 1% reduction in serum cholesterol concentration is associated with an estimated 2% to 3% reduction in risk for coronary heart disease, regular intake of FM containing an appropriate strain of L. acidophilus has the potential of reducing risk for coronary heart disease by 6 to 10%. (5)
1. Gaon D, Garmendia C, Murrielo NO, de Cucco Games A, Cerchio A, Quintas R, González SN, Oliver G.Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina (B Aires). 2002;62(2):159-63
2. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, Kim YH, Kim JJ, Rhee JC, Rhee PL Therapeutic Effect of Lactobacillus acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome. Dig Dis Sci. 2008 Feb 15 [Epub ahead of print
3. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007 Jul;13(7):657-64.
4. Clancy RL, Gleeson M, Cox A, Callister R, Dorrington M, D'Este C, Pang G, Pyne D, Fricker P, Henriksson A. Reversal in fatigued athletes of a defect in interferon gamma secretion after administration of Lactobacillus acidophilus. Br J Sports Med. 2006 Apr;40(4):351-4.
5. Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr. 1999 Feb;18(1):43-50